📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Laboratory Manual (TILA278-201)

Document ID: TMF-011
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH E6(R3)

Laboratory Manual — TILA278-201

Central and local laboratory procedures for TILA278-201, a Phase 2b, randomized, double-blind, placebo-controlled 12-week induction study of TILA-278 (an anti-TL1A/anti–IL-22R bispecific humanized IgG1 monoclonal antibody administered subcutaneously) in adults with moderate-to-severe Ulcerative Colitis, sponsored by Virtual Biopharma Inc. This manual governs sample collection, handling, processing, storage, and shipment for the safety analyses, the disease-activity assessments that support the Modified Mayo Score, and the specialty pharmacokinetic (PK) and anti-drug antibody (ADA) analyses, together with the applicable reference ranges and flagging conventions. It is a controlled operational document to be read in conjunction with the protocol, the central laboratory work instructions, and the bioanalytical study plans. ICH E6(R3).

1. Purpose and Scope

This manual standardizes all clinical laboratory activities across participating sites so that results are generated, reported, and reconciled under a single, harmonized process regardless of geography. It covers: (i) protocol-required safety chemistry, hematology, coagulation, and urinalysis; (ii) eligibility-related infectious disease and pregnancy testing; (iii) disease-activity biomarkers supporting the Modified Mayo Score; (iv) central endoscopy video capture and blinded central reading; (v) serum drug-concentration (PK) sampling supporting the target-mediated disposition characterization of TILA-278; and (vi) tiered immunogenicity (ADA) testing. Approximately 900 participants are randomized 1:1:1 to high-dose TILA-278, low-dose TILA-278, or matching placebo; every participant is sampled according to the schedule below through the end of the 12-week induction period and the safety follow-up.

2. Roles and Responsibilities

• Central laboratory: Provides collection kits, requisitions, barcoded labels, and pre-addressed courier materials; performs the core safety hematology, chemistry, coagulation, urinalysis, and disease-activity biomarker analyses; issues reference-range–adjusted reports to sites and the sponsor's data flow; and maintains temperature-monitored storage of retained aliquots.
• Specialty bioanalytical laboratory: Performs the validated PK (serum TILA-278 concentration) and immunogenicity (ADA screening, confirmatory, titer, and neutralizing-antibody) assays under separate bioanalytical study plans; receives and stores frozen serum aliquots and maintains the sample chain of custody for those matrices.
• Central imaging/endoscopy reading facility: Receives de-identified endoscopy video, confirms technical adequacy, and provides the blinded central Mayo endoscopic subscore used in the Modified Mayo Score.
• Local (site) laboratory: Used only where a real-time local result is required for participant safety (for example, a same-day pregnancy result before dosing, or an urgent safety value); local results are captured with the local reference range and method. Local laboratories provide current certification/accreditation, a normal reference-range table, and analyst qualifications for the trial file.
• Investigator/site staff: Confirm participant identity and fasting status where required, collect and process samples per this manual, verify labeling against the requisition, and arrange same-day dispatch within the specified stability window.

3. Laboratory Assessment Schedule

Samples are collected at Screening, at Day 1 (Baseline, Week 0, pre-dose), and at Weeks 2, 4, 8, and 12 (end of induction), with a Safety Follow-up visit after the last dose; unscheduled/early-termination visits repeat the safety and, where relevant, the PK and ADA panels. The applicable panel per visit is:

• Hematology (every visit): complete blood count with white-cell differential, platelet count, hemoglobin, hematocrit, and red-cell indices.
• Serum chemistry (every visit): hepatic panel (ALT, AST, alkaline phosphatase, total and direct bilirubin, albumin, total protein), renal panel (creatinine with estimated GFR, urea/BUN), electrolytes (sodium, potassium, chloride, bicarbonate), glucose, calcium, phosphate, and lipase.
• Coagulation (Screening and as clinically indicated): prothrombin time/INR and activated partial thromboplastin time.
• Urinalysis (Screening, Baseline, and end of induction): dipstick with reflex microscopy on abnormal findings.
• Infectious disease and eligibility testing (Screening): as specified in Section 5.
• Pregnancy testing: serum β-hCG at Screening for women of childbearing potential, with urine β-hCG prior to dosing at on-treatment visits.
• Disease-activity biomarkers (Screening and specified on-treatment visits): fecal calprotectin and high-sensitivity C-reactive protein.
• Pharmacokinetics: pre-dose (trough) serum sampling at dosing visits and at end of induction and Safety Follow-up, per Section 8.
• Immunogenicity (ADA): serum sampling at Baseline (pre-dose), Weeks 4 and 12, and Safety Follow-up, per Section 9.

Blood volumes per visit are itemized in the collection-kit insert; the cumulative volume remains within protocol-defined limits for the induction period.

4. Safety Analytes and Reference Ranges

The central laboratory analyzes safety samples on qualified, maintained platforms with documented calibration and internal quality control. Age- and sex-appropriate reference ranges are supplied by the central laboratory and appended to this manual; where local laboratories are used, the corresponding local reference range accompanies each result. Because TILA-278 is an immunomodulatory biologic, particular attention is given to hepatic transaminases, absolute neutrophil count, and lymphocyte count; trends across visits are monitored in addition to single-point flags.

5. Screening and Eligibility-Specific Testing

At Screening, eligibility-relevant infection and organ-function testing is performed to support the benefit–risk assessment appropriate to an immunomodulatory therapy:

• Latent/active tuberculosis: interferon-γ release assay (with chest imaging per protocol for positive/indeterminate results).
• Viral hepatitis: hepatitis B surface antigen, hepatitis B core antibody, and hepatitis C antibody, with reflex confirmatory/viral-load testing per protocol.
• HIV serology per protocol and local requirements.
• Enteric pathogens: stool testing for Clostridioides difficile toxin and, where indicated, routine enteric pathogens, to exclude infective causes of the presenting colitis.

6. Disease-Activity Biomarkers

Fecal calprotectin and high-sensitivity C-reactive protein are collected as objective inflammatory markers supporting interpretation of the Modified Mayo Score and the endoscopic response. Stool for calprotectin is collected by the participant into the supplied container ahead of the visit; the specimen is kept refrigerated, transferred to site, frozen, and shipped frozen to the central laboratory. Pre-analytical timing and temperature are recorded because calprotectin stability is temperature- and time-sensitive.

7. Central Endoscopy Reading

The Mayo endoscopic subscore that contributes to the Modified Mayo Score is determined by blinded central reading. Video ileocolonoscopy is performed per the endoscopy procedure guide, captured to the specified format, de-identified, and uploaded to the central imaging facility. Only technically adequate, centrally read scores are used for the endpoint. The Modified Mayo Score comprises the stool-frequency subscore, the rectal-bleeding subscore, and the centrally read endoscopic subscore (the Physician's Global Assessment component is excluded), consistent with the protocol definition of clinical remission (Modified Mayo Score ≤ 2 with no individual subscore > 1).

8. Pharmacokinetic Sampling

Serum concentrations of TILA-278 are measured with a validated ligand-binding assay under a dedicated bioanalytical study plan. Because TILA-278 exhibits target-mediated drug disposition, the sampling schedule is designed to characterize nonlinear, concentration-dependent clearance: pre-dose (trough) samples are drawn at each dosing visit, with additional samples at end of induction and Safety Follow-up to describe the terminal phase. For each PK draw, the exact date and time of the sample and of the most recent TILA-278 subcutaneous administration are recorded, together with the injection site, since these anchor the population-PK analysis. Samples are processed to serum, aliquoted, frozen, and shipped frozen to the specialty laboratory (Section 10–11).

9. Immunogenicity (ADA) Sampling and Testing

Immunogenicity is assessed with a multi-tiered strategy under a validated bioanalytical study plan: a screening assay, a confirmatory (specificity) assay for screen-positive samples, titer determination for confirmed positives, and a neutralizing-antibody assay. Assay drug tolerance and the potential for TILA-278 in circulation to interfere with ADA detection are accounted for in sample timing; the pre-dose Baseline sample establishes the individual baseline, and on-treatment/Safety Follow-up samples support treatment-emergent and treatment-boosted classifications. PK and ADA results are interpreted together to contextualize exposure, loss of response, and any hypersensitivity signals. ADA serum is processed, aliquoted, and frozen identically to PK samples; PK and ADA aliquots are drawn from separate, clearly distinguished tubes to prevent misidentification.

10. Sample Collection, Processing, and Handling

Samples are collected into the tube types specified in the collection-kit insert (for example, EDTA whole blood for hematology; serum-separator or plain serum tubes for chemistry, PK, and ADA; citrate for coagulation). Serum tubes are allowed to clot fully before centrifugation at the specified speed and duration; plasma and serum are separated promptly and aliquoted into pre-barcoded cryovials. Processing start and end times, centrifuge parameters, and any hemolysis, lipemia, or icterus are recorded. Whole-blood hematology and routine chemistry are analyzed within their validated stability windows; PK, ADA, and fecal-calprotectin aliquots are frozen without delay.

11. Labeling, Storage, and Shipment

Every aliquot carries a unique barcoded label linking it to the participant, visit, and matrix without disclosing personal identifiers; labels are verified against the requisition before storage. Storage and transport follow a defined cold chain: ambient, refrigerated (2–8 °C), frozen (−20 °C or colder), and deep-frozen (≤ −70 °C) as specified per analyte. Refrigerated and frozen samples ship with validated coolant or dry ice, respectively, using the pre-qualified courier and the pre-addressed, temperature-appropriate shipper. Shipments are dispatched within the specified stability window, and international consignments include the required customs and biological-substance documentation. Temperature excursions are recorded and reported to the central/specialty laboratory for an impact assessment before the affected samples are analyzed.

12. Reference Ranges, Flagging, and Alert Values

Reported results are flagged relative to the applicable reference range (High/Low) and, separately, against protocol-defined clinically significant thresholds. Predefined alert (panic) values are communicated by the laboratory to the site without delay so the investigator can act on participant safety; examples relevant to this population and modality include marked transaminase elevation (for instance, ALT or AST > 3× the upper limit of normal, with escalation and closer monitoring at higher multiples), significant neutropenia or lymphopenia, and clinically significant electrolyte or renal derangements. All alert notifications are documented with the date, time, recipient, and acknowledgment.

13. Bioanalytical Method Validation and Documentation

Safety assays are performed under the central laboratory's quality system with method validation, calibration, and internal/external quality control consistent with recognized clinical-laboratory standards. The PK ligand-binding assay and the tiered ADA assays are validated in accordance with applicable bioanalytical method-validation expectations and documented in their respective bioanalytical study plans and reports, addressing selectivity, sensitivity, drug tolerance, precision, accuracy, and stability appropriate to a monoclonal-antibody analyte. Assay characteristics relevant to product quality attributes are consistent with the specifications framework for the biologic. Validation and method documentation are retained in the trial file.

14. Sample Retention, Chain of Custody, and Reconciliation

An auditable chain of custody is maintained from collection through analysis, storage, and disposition. Retained safety, PK, and ADA aliquots are stored under monitored conditions for the retention period defined in the protocol and informed-consent documentation and are used only for the analyses to which participants consented. Sample inventories are reconciled periodically against the requisitions and the electronic data capture record; discrepancies, missing samples, and excursion-affected samples are documented and resolved.

15. Data Management and Query Handling

Laboratory results flow to the sponsor's data pipeline under the agreed transfer specification, with reference ranges, flags, and result metadata. Sites review reports promptly, acknowledge alerts, and record clinical significance where required. Queries on missing, out-of-window, or discrepant samples are managed through the laboratory and data-management query processes and are resolved before database lock for the induction analysis.

16. Biosafety and Specimen Handling

All specimens are handled as potentially infectious using standard precautions and local biosafety requirements. Spills, sharps handling, and waste disposal follow site procedures; personnel handling samples are trained accordingly, and this training is documented in the trial file.